Vascular Endothelial Growth Factor Plasmid «Neovasculgen» in the Treatment of Chronic Limb Ischemia

  • #VS 02-EP-7
  • Vascular Surgery. E-POSTER (ORAL) SESSION 2
  • E-Poster (oral)

Vascular Endothelial Growth Factor Plasmid «Neovasculgen» in the Treatment of Chronic Limb Ischemia

Olga A. Demidova 1, Leo A. Bockeria 1, Olga L. Bockeria 1, Valery S. Arakelyan 1, Roman V. Deev 2, Marina A. Karaseva  1, Astine G. Airoyn 1

Bakulev’ Scientific Center of Cardiovascular Surgery, Moscow, Russia; PJSC Human Stem Cells Institute, Moscow, Russia;

Date, time and location: 2018.05.26 13:30, Exhibition area, 1st Floor. Zone – B



The purpose of our study was to assess the efficacy of vascular endothelial growth factor VEGF165plasmid in the treatment of chronic limb ischemia.


20 patients, mean age63+/-9,3 years with chronic limb ischemia involved in the study in 2017. Atherosclerosis was determined as etiologic factor in all patients with diabetes in 6 cases (30 %). In all patients we revealed multisegmental inoperable injury of lower extremity arteries. Patients underwent treatment with 1200 mkg ofvascular endothelial growth factorplasmid twice with an interval of 14 days.Stimulator was injected in gastrocnemius muscle suffer fromischemia limb.Concomitant therapy included only acetylsalicylic acid in dose 100 mg per day. Follow-up was performed in 1, 3 and 6 months after injection of stimulator of angiogenesis.


Clinical improvement observed in all patientsat3 months after theinjection of a stimulator of angiogenesis. Maximum improvement was +2 by Rutherford. Increasing of the maximum walking duration was observed at the whole follow-up period. At 3-month a significant increase in the partial oxygen pressure on the skin by 23.0+/-0,08 mm Hg and ankle brachial pressure index 0,21+/0,11 has been found. Growth of the collateral network density at the 6-month, evaluated by computer tomoangiography. According to the SF-36 questionnaire, patients reported improvement in the quality of their life.

The use of vascular endothelial growth factorplasmid «Neovasculgen» can improve treatment outcomes in patients with chronic lower limb ischemia. Positive dynamics of clinical condition is limited by a moderate improvement.

To top